Rare diseases
Investigational molecules
Locations
Ul. Szaserów 128 (budynek główny, blok E-1, piętro 3), 04-141 Warsaw, Poland
The Clinical Research Support Center (CWBK) of the Wojskowy Instytut Medyczny – Państwowy Instytut Badawczy is a modern unit providing comprehensive support for the conduct of commercial and non‑commercial clinical trials. Operating within the framework of one of the largest and most experienced clinical hospitals in Poland, we combine the potential of a multi‑specialty medical center with the highest quality standards and state‑of‑the‑art organizational and research infrastructure.
WIM–PIB is a multi‑profile, highly specialized clinical hospital with the highest level of referral capacity, equipped with modern diagnostic, laboratory, and therapeutic infrastructure. The Institute provides access to a full suite of resources necessary for conducting clinical trials, including, among others, imaging diagnostics, diagnostic laboratories, histopathology, nuclear medicine, endoscopy suites, as well as numerous wards and specialist outpatient clinics. Such extensive capabilities enable the execution of research projects in virtually all major areas of contemporary medicine.
CWBK provides comprehensive study support at every stage of execution. Sponsors, investigators, and patients have access to dedicated infrastructure, including, among others, monitored hospital wards, infusion rooms, physician offices, procedure rooms with phlebotomy points, and facilities for processing and storing biological material (with continuous parameter monitoring). The CWBK team consists of experienced professionals handling clinical trial coordination, contracting, data management, quality monitoring, and administrative support. CWBK also employs its own medical staff (physicians, nursing personnel) responsible for implementing clinical trial procedures and providing medical care during the patient’s stay at the center.
One of the cornerstones of CWBK’s operations is its quality management system. In the clinical research domain, Standard Operating Procedures (SOPs) have been implemented, and quality specialists oversee compliance of studies with applicable laws, Good Clinical Practice (GCP) principles, and internal procedures. CWBK’s quality system is integrated with the hospital quality management system operating within WIM–PIB, allowing research processes to benefit from organizational solutions developed in an accredited, highly specialized clinical hospital. This approach provides sponsors, investigators, and study participants with the highest level of safety, process transparency, and compliance with regulatory requirements and international standards.
WIM–PIB has been conducting clinical trials for many years across a broad spectrum of medical fields. The Institute’s experience encompasses both commercial and non‑commercial studies of medicinal products and medical devices. The multidisciplinary nature of WIM–PIB enables effective execution of trials in numerous therapeutic areas while maintaining the highest standards of quality, safety, and ethics.
Wojskowy Instytut Medyczny Państwowy Instytut Badawczy in Warsaw, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Systemic lupus erythematosus, Breast cancer, Ischaemic stroke, and other specialisations. This site conducts important research.
At Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy in Warsaw, clinical research in respiratory tract diseases focuses on serious lung conditions such as idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. These studies are designed to evaluate new treatment options and better understand their impact on lung function and symptom control.
This area reflects a strong interest in improving care for patients with chronic and often hard-to-treat pulmonary disease.
The site also carries out extensive research in neoplasms, including acute myeloid leukemia, myelodysplastic syndrome, breast cancer, advanced non-small cell lung cancer, and head and neck cancer. These trials are mainly aimed at testing new cancer therapies, improving response rates, and understanding how treatments work in difficult-to-treat disease settings.
This oncology portfolio shows active work on both early treatment response and longer-term disease control.
In cardiovascular diseases, the research includes coronary artery disease, heart failure, and prevention of ischemic stroke after recent cerebrovascular events. These trials are focused on improving diagnosis, reducing complications, and testing therapies that may lower the risk of major cardiovascular outcomes.
The cardiovascular program combines treatment and diagnostic research to support earlier and more effective care.
Clinical trials in immune system diseases at this institution cover giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, and ulcerative colitis. The site also conducts research in rare diseases, including ANCA-associated vasculitis, Sjögren’s syndrome, and hereditary angioedema. The main purpose is to compare new therapies with established treatments and to improve control of inflammation, symptoms, and disease activity.
This research supports broader efforts to find safer and more effective long-term management strategies for autoimmune conditions.
The site’s trial portfolio also includes musculoskeletal diseases, nervous system diseases, and female urogenital diseases. Research in these areas addresses endometriosis-related pain, multiple sclerosis, and other conditions where better symptom relief, disease control, or treatment tolerance is needed.
These studies broaden the research focus beyond major internal medicine specialties and into conditions that strongly affect daily functioning.
The site conducts clinical trials across a broad range of kidney diseases, from chronic kidney disease to end-stage kidney disease in patients on maintenance dialysis. A significant part of this work concerns glomerular diseases, including nephrotic syndrome, focal segmental glomerulosclerosis, and the rare Alport syndrome.
This is an important area for patients with chronic and rare kidney diseases, where access to new therapies may delay the need for renal replacement therapy.
In dermatology, the site carries out research in chronic inflammatory skin diseases such as moderate to severe atopic dermatitis and hidradenitis suppurativa. Projects also address rare conditions, including pyoderma gangrenosum and alopecia areata, as well as the treatment of skin toxicities associated with cancer therapy.
This research is particularly relevant for patients whose disease is not adequately controlled by standard treatment.
The site’s research profile also includes ophthalmology. Studies cover pharmacological treatment of acquired blepharoptosis with eye drops, as well as projects at the interface of ophthalmology and oncology in uveal melanoma.
This area combines ophthalmic diagnosis and treatment with the multidisciplinary care available at the site.
Clinical trials currently enrolling participants at this site.
PolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandPolandTell us about your condition – we search every trial in Europe and connect you with the right site.
